Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-03-05 4:59 pm Unchanged | 13D | MOONLAKE IMMUNOTHERAPEUTICS CO MLTX | BIOTECHNOLOGY VALUE FUND L P | 21,751,284 34.6% | 0 (Unchanged) | View |
2024-02-22 4:45 pm Unchanged | 13G | ENGENE HLDGS INC ENGN | BIOTECHNOLOGY VALUE FUND L P | 3,196,439 7.2% | 0 (Unchanged) | View |
2024-02-14 10:30 am Sale | 13G | ACLARIS THERAPEUTICS INC ACRS | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -3,360,941 (Position Closed) | View |
2024-02-14 10:28 am Sale | 13G | AILERON THERAPEUTICS INC N ALRN | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -236,835 (Position Closed) | View |
2024-02-14 10:26 am Purchase | 13G | ANNEXON INC ANNX | BIOTECHNOLOGY VALUE FUND L P | 7,000,000 8.9% | 3,219,306 (+85.15%) | View |
2024-02-14 10:24 am Purchase | 13G | VERSARTIS INC ARAV | BIOTECHNOLOGY VALUE FUND L P | 8,164,510 9.99% | 2,055,452 (+33.65%) | View |
2024-02-14 10:22 am Purchase | 13G | ASLAN PHARMACEUTICALS LTD SPON ASLN | BIOTECHNOLOGY VALUE FUND L P | 43,344,975 9.99% | 43,344,975 (New Position) | View |
2024-02-14 10:20 am Sale | 13G | BIONOMICS LTD ADS BNOX | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -170,089,885 (Position Closed) | View |
2024-02-14 10:18 am Purchase | 13G | CIDARA THERAPEUTICS INC CDTX | BIOTECHNOLOGY VALUE FUND L P | 9,275,527 9.99% | 2,414,400 (+35.19%) | View |
2024-02-14 10:16 am Sale | 13G | CULLINAN ONCOLOGY, INC. CGEM | BIOTECHNOLOGY VALUE FUND L P | 4,393,321 9.99% | -3,115,738 (-41.49%) | View |
2024-02-14 10:13 am Purchase | 13G | CENTESSA PHARMACEUTICALS PLC S CNTA | BIOTECHNOLOGY VALUE FUND L P | 8,774,570 9% | 1,880,225 (+27.27%) | View |
2024-02-14 10:11 am Sale | 13G | CRINETICS PHARMACEUTICALS INC CRNX | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -2,736,613 (Position Closed) | View |
2024-02-14 10:09 am Purchase | 13G | CYTOMX THERAPEUTICS INC CTMX | BIOTECHNOLOGY VALUE FUND L P | 6,702,889 9.99% | 107,088 (+1.62%) | View |
2024-02-14 10:08 am Purchase | 13G | DELCATH SYS INC DCTH | BIOTECHNOLOGY VALUE FUND L P | 2,338,426 9.99% | 776,912 (+49.75%) | View |
2024-02-14 10:06 am Purchase | 13G | ELEDON PHARMACEUTICALS INC ELDN | BIOTECHNOLOGY VALUE FUND L P | 4,326,710 17.9% | 2,000,000 (+85.96%) | View |
2024-02-14 10:01 am Purchase | 13G | ELEVATION ONCOLOGY INC ELEV | BIOTECHNOLOGY VALUE FUND L P | 4,450,885 9.99% | 2,138,685 (+92.50%) | View |
2024-02-14 09:58 am Purchase | 13G | 89BIO INC ETNB | BIOTECHNOLOGY VALUE FUND L P | 7,568,480 7.8% | 4,047,354 (+114.94%) | View |
2024-02-14 09:56 am Unchanged | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | BIOTECHNOLOGY VALUE FUND L P | 4,007,413 9.4% | 0 (Unchanged) | View |
2024-02-14 09:54 am Purchase | 13G | GH RESH PLC SHS GHRS | BIOTECHNOLOGY VALUE FUND L P | 10,400,158 19.99% | 1,125,000 (+12.13%) | View |
2024-02-14 09:52 am Unchanged | 13G | GALMED PHARMACEUTICALS LTD. SH GLMD | BIOTECHNOLOGY VALUE FUND L P | 0 0% | 0 (Unchanged) | View |